Linsitinib Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Linsitinib Growth

(1) High unmet need in adrenocortical carcinoma (ACC)

ACC is an ultra-rare and aggressive cancer with an incidence of only 0.7-2 cases per million annually, and nearly 40-60% of patients present with advanced/metastatic disease at diagnosis, where treatment options remain limited largely to surgery, mitotane, and EDP chemotherapy. Median survival in metastatic ACC remains poor (~1 year in many studies), creating strong demand for targeted therapies. Because of this unmet need, linsitinib initially gained significant interest as a potential targeted alternative.

(2) Orphan drug designation provided regulatory/commercial incentives

In March 2012, the FDA granted orphan drug designation to Linsitinib for ACC.

For rare oncology drugs, orphan exclusivity often enables premium pricing despite small patient populations. This was one of the biggest early commercial drivers for linsitinib.

(3) Strong biological rationale targeting IGF-2 overexpression in ACC

Approximately 85-90% of ACC tumors overexpress IGF-2, making the IGF signaling pathway an attractive therapeutic target. Preclinical studies showed that linsitinib inhibited tumor proliferation and promoted apoptosis by blocking both IGF-1R and insulin receptor signaling. This strong scientific rationale initially differentiated it from traditional chemotherapy and drove investor and clinical interest.

(4) Oral administration advantage

Unlike many oncology biologics that require infusion, Linsitinib was developed as an oral therapy, offering:

• Better patient convenience
• Lower administration costs
• Potential use in outpatient settings
• Easier long-term maintenance therapy adoption

In rare cancers where patients often undergo multiple treatment regimens, oral convenience can improve adoption if efficacy is demonstrated.

(5) Potential biomarker-driven opportunity despite Phase III setback

The biggest commercial setback came when Linsitinib failed in a Phase III trial published in The Lancet Oncology. The study showed that linsitinib did not significantly improve overall survival versus placebo in advanced ACC patients. However, investigators noted that a small subgroup of long-term responders existed, suggesting future potential in biomarker-selected populations. If precision oncology approaches identify responders, the drug could still see niche revival.

Linsitinib Recent Developments

In January 2025, Sling Therapeutics, a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), announced topline efficacy and safety data from the Phase IIb/III LIDS trial of Linsitinib in patients with active, moderate to severe TED.

"Linsitinib Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Linsitinib for potential indication like Graves ophthalmopathy and Autoimmune disorders in the 7MM. A detailed picture of Linsitinib's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Linsitinib for potential indications. The Linsitinib market report provides insights about Linsitinib's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Linsitinib performance, future market assessments inclusive of the Linsitinib market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Linsitinib sales forecasts, along with factors driving its market.

Linsitinib Drug Summary

Linsitinib (also known as OSI-906) is an orally bioavailable, small-molecule dual inhibitor of the Insulin-like Growth Factor 1 Receptor signaling and insulin receptor (IR) tyrosine kinases, developed to block tumor growth and survival pathways driven by aberrant IGF signaling. By selectively inhibiting phosphorylation of IGF-1R and IR, Linsitinib suppresses downstream PI3K/AKT and MAPK signaling, thereby reducing cellular proliferation and promoting apoptosis in cancers and endocrine disorders linked to IGF-2 overexpression. The drug has been investigated across multiple indications, including adrenocortical carcinoma, where it advanced into Phase III evaluation, as well as other solid tumors such as non-small cell lung cancer and breast cancer. Although it showed manageable safety and some clinical activity, particularly in biomarker-selected populations, its Phase III trial in advanced Adrenocortical Carcinoma failed to meet overall survival endpoints, limiting further broad oncology development; however, interest in the molecule has persisted in rare endocrine tumors and research settings exploring IGF pathway inhibition. The report provides Linsitinib's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Linsitinib Market Report

The report provides insights into:

• A comprehensive product overview including the Linsitinib MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy and Autoimmune disorders.
• Elaborated details on Linsitinib regulatory milestones and other development activities have been provided in Linsitinib market report.
• The report also highlights Linsitinib's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Linsitinib market report also covers the patents information, generic entry and impact on cost cut.
• The Linsitinib market report contains current and forecasted Linsitinib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Linsitinib market report also features the SWOT analysis with analyst views for Linsitinib in potential indications.

Methodology:

The Linsitinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Linsitinib Analytical Perspective by DelveInsight

• In-depth Linsitinib Market Assessment

This Linsitinib sales market forecast report provides a detailed market assessment of Linsitinib for potential indication like Graves ophthalmopathy and Autoimmune disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Linsitinib sales data uptil 2034.

• Linsitinib Clinical Assessment

The Linsitinib market report provides the clinical trials information of Linsitinib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Linsitinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Linsitinib Market Potential & Revenue Forecast

• Projected market size for the Linsitinib and its key indications
• Estimated Linsitinib sales potential (Linsitinib peak sales forecasts)
• Linsitinib Pricing strategies and reimbursement landscape

Linsitinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Linsitinib Market positioning compared to existing treatments
• Linsitinib Strengths & weaknesses relative to competitors

Linsitinib Regulatory & Commercial Milestones

• Linsitinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Linsitinib Clinical Differentiation

• Linsitinib Efficacy & safety advantages over existing drugs
• Linsitinib Unique selling points

Linsitinib Market Report Highlights

• In the coming years, the Linsitinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Linsitinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Linsitinib's dominance.
• Other emerging products for Graves ophthalmopathy and Autoimmune disorders are expected to give tough market competition to Linsitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Linsitinib in potential indications.
• Analyse Linsitinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Linsitinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Linsitinib in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Linsitinib? How strong is Linsitinib's clinical and commercial performance?
• What is Linsitinib's clinical trial status in each individual indications such as Graves ophthalmopathy and Autoimmune disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Linsitinib Manufacturers?
• What are the key designations that have been granted to Linsitinib for potential indications? How are they going to impact Linsitinib's penetration in various geographies?
• What is the current and forecasted Linsitinib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Linsitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Linsitinib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Linsitinib? What is the duration of therapy and what are the geographical variations in cost per patient?